30 October 2009, Mumbai, India

GlaxoSmithKline Pharmaceuticals Net Sales up 12% in Third Quarter of FY 2009
Profit before Investment Income and Taxes grows by 13%

GlaxoSmithKline Pharmaceuticals Limited has announced its financial results for the third quarter ended 30th September 2009. The Company posted Net Sales growth of 12% compared to the previous quarter, while Profit before Investment Income and Taxes grew by 13% on a comparable basis.

Commenting on the performance, Dr. Hasit B. Joshipura, Managing Director, said, “Sales during the quarter have shown growth across mass, mass speciality, vaccines and speciality therapies. Recent launches of Tykerb for refractory breast cancer, Benitec an anti-hypertensive drug from Daiichi Sankyo and Cervarix for cervical cancer are making steady progress. Vaccines have recorded strong growth with the rotaviral diarrhea vaccine tracking ahead of plan”.

About GlaxoSmithKline:

GlaxoSmithKline Pharmaceuticals Limited is a subsidiary of GlaxoSmithKline plc, one of the world's leading research-based pharmaceutical and healthcare companies, committed to improving the quality of human life by enabling people to do more, feel better and live longer. For more information, visit www.gsk-india.com.

For enquiries, please contact:

Rupali Kalav
Manager, Corporate Communications +91 22 24959208
rupali.v.kalav@gsk.com